Chongrui Xu, MD, PhD, Guangdong Lung Cancer Institute, Guangzhou, China, gives an overview of findings from a Phase I trial (NCT05005234) of IBI351, a novel inhibitor of KRAS G12C, in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC). IBI351 was found to be well tolerated in patients, and a promising efficacy was additionally reported. The maximum tolerated dose was also determined to be 600mg twice daily. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.